DBV Technologies

DBV Technologies has global headquarters in Montrouge, France and New York, NY.

DBV Technologies
177-181 avenue Pierre Brossolette - 92120 Montrouge – France

www.dbv-technologies.com

DBV Technologies is a clinical-stage biopharmaceutical company founded in 2002, developing immunotherapy product candidates utilizing a novel proprietary technology platform based on investigational epicutaneous immunotherapy, which aims at delivering biologically active compounds to the immune system through intact skin. The most advanced product candidates are currently being developed for the treatment of food allergies.

Food allergies are an increasingly prevalent condition worldwide with no currently approved treatments.